DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response and some HR+...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Denise M., Yau, Christina, Sanil, Ashish, Glas, Annuska, Petricoin, Emanuel, Wulfkuhle, Julia, Severson, Tesa M., Linn, Sabine, Brown-Swigart, Lamorna, Hirst, Gillian, Buxton, Meredith, DeMichele, Angela, Hylton, Nola, Symmans, Fraser, Yee, Doug, Paoloni, Melissa, Esserman, Laura, Berry, Don, Rugo, Hope, Olopade, Olufunmilayo, van ‘t Veer, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572474/
https://www.ncbi.nlm.nih.gov/pubmed/28948212
http://dx.doi.org/10.1038/s41523-017-0025-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572474/
https://www.ncbi.nlm.nih.gov/pubmed/28948212
http://dx.doi.org/10.1038/s41523-017-0025-7

Ejemplares similares